Prothena Corporation plc (PRTA)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
As of 03:27PM EDT. Market open.
| Previous close | 20.34 |
| Open | 20.59 |
| Bid | 21.81 x 100 |
| Ask | 21.98 x 100 |
| Day's range | 20.26 - 22.00 |
| 52-week range | 19.65 - 79.65 |
| Volume | |
| Avg. volume | 630,540 |
| Market cap | 1.175B |
| Beta (5Y monthly) | 0.24 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.76 |
| Earnings date | 01 May 2024 - 03 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 66.77 |
ZacksEarnings Preview: Prothena (PRTA) Q1 Earnings Expected to Decline
Prothena (PRTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Business WireProthena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma
DUBLIN, April 15, 2024--Prothena today announced a publication related to the mechanism of action, pharmacological characteristics, and clinical utility of birtamimab.
Investor's Business DailyRace To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback
The Alzheimer's treatment space is heating up — and could soon leave Eli Lilly's embattled drug, donanemab, in the dust, experts say.
© 2024 Yahoo. All rights reserved.